September 2025 - Page 14 of 28

WednesdaySep 17, 2025 9:00 am

Oncotelic Therapeutics Inc. (OTLC) Champions Targeted RNA Therapy for Underserved Cancers

On the global stage, the Cancer Atlas estimates a dramatic rise in cancer cases, adding urgency to the need for therapeutic innovation Oncotelic’s mission focuses on developing first-in-class RNA therapeutics and small-molecule drugs to serve high-unmet-need cancers and rare pediatric diseases This year, the company achieved a major milestone by successfully completing a phase 1 clinical trial evaluating OT-101 combining Interleukin-2 In a landscape where cancer and underserved diseases continue to devastate millions, the demand for groundbreaking RNA-based, immunotherapeutic, and targeted treatments has never been more urgent. Oncotelic Therapeutics (OTCQB: OTLC) is answering this call with pioneering RNA candidates and strategic programs aimed…

TuesdaySep 16, 2025 11:10 am

QualityStocksNewsBreaks – Safe Pro Group Inc. (NASDAQ: SPAI) Highlighted in Northland Capital Markets Report on AI Integration With Red Cat Black Widow Drone

Safe Pro Group (NASDAQ: SPAI) was featured in a Northland Capital Markets research report that reaffirmed its Outperform rating and $13 price target. The report, authored by analyst Michael Latimore, detailed Red Cat’s announcement to embed Safe Pro’s small object threat detection AI into its Black Widow drone, significantly expanding its ability to detect over 150 types of small threats including landmines and unexploded ordnance. Northland noted the integration could allow real-time battlefield threat mapping and communications without requiring drones to return to base, creating strong demand potential among military customers. The firm expects Safe Pro to generate licensing fees…

TuesdaySep 16, 2025 10:50 am

QualityStocksNewsBreaks – Ucore Rare Metals Inc. (TSXV: UCU) (OTCQX: UURAF) and Metallium (ASX: MTM; OTCQX: MTMCF) Form Strategic Collaboration to Advance Rare Earth Refining

Ucore Rare Metals (TSXV: UCU) (OTCQX: UURAF) announced a strategic technology collaboration with Metallium Limited (ASX: MTM; OTCQX: MTMCF) to integrate Metallium’s Flash Joule Heating (FJH) technology with Ucore’s RapidSX(TM) separation platform. The partnership aims to develop a modular, U.S.-based refining solution capable of processing both conventional rare earth concentrates and alternative feedstocks such as magnet scrap, e-waste, and lighting waste. Initial stages will focus on bench-scale and pilot testing to produce mixed rare earth chlorides for processing at Ucore’s facilities, targeting high-value outputs including NdPr, Dy, and Tb. Executives emphasized the collaboration’s potential to expand feedstock sources, enhance recovery…

TuesdaySep 16, 2025 10:41 am

QualityStocksNewsBreaks – Wearable Devices Ltd. (NASDAQ: WLDS) Spotlighted in NetworkNewsWire Editorial on AI-Powered Wearables

Wearable Devices (NASDAQ: WLDS) announced its inclusion in a NetworkNewsWire (“NNW”) editorial titled “AI-Powered Wearables Transform How Consumers Interact with Everyday Technology” (https://nnw.fm/AYAOv). The article highlights growing global demand for neural interface technologies as consumers and industries seek seamless, gesture-based control beyond touchscreens and voice assistants. Positioned at the forefront of this trend, Wearable Devices has introduced its AI-powered Mudra Band for Apple Watch and the Mudra Link platform, offering intuitive, touchless interaction across ecosystems. To view the full press release, visit https://ibn.fm/KkOCg About Wearable Devices Ltd. Wearable Devices Ltd. is a growth company pioneering human-computer interaction through its AI-powered neural…

TuesdaySep 16, 2025 10:30 am

QualityStocksNewsBreaks – Lantern Pharma (NASDAQ: LTRN) Completes Phase 1a Trial of LP-184 With Favorable Safety, PK Profile and Early Antitumor Activity

Lantern Pharma (NASDAQ: LTRN), an AI-driven oncology company, announced the successful completion of its Phase 1a clinical trial for LP-184 (NCT05933265), which met all primary endpoints, showing a favorable safety and pharmacokinetic profile with early signs of antitumor activity. The open-label study in 63 patients with advanced relapsed or refractory solid tumors, including GBM, demonstrated disease control in 48% of evaluable patients at therapeutic dose levels, with notable responses in DDR-deficient cancers such as NSCLC, colon cancer, thymic carcinoma, and GIST. No dose-limiting toxicities were observed, and adverse events were predominantly mild. Lantern plans to advance LP-184 into Phase 1b…

TuesdaySep 16, 2025 10:30 am

D-Wave Quantum Inc. (NYSE: QBTS) Announces First-Ever Qubits Japan 2025 Quantum Computing User Conference

D-Wave is hosting a quantum computing user conference called Qubits Japan 2025 in Tokyo on September 17, 2025. The event is themed “Quantum Realized” and will feature presentations highlighting customer success stories, technical roadmap updates, scientific achievements and advancements in quantum AI. This follows an 83% increase in bookings for D-Wave’s annealing quantum computing technology in the Asia Pacific region as organizations develop optimization and quantum AI applications D-Wave Quantum Inc. (NYSE: QBTS) (“D-Wave” or “The Company”), a leader in quantum computing systems, software, and services, recently announced that it is hosting its first-ever Qubits Japan 2025 quantum computing user…

TuesdaySep 16, 2025 10:10 am

QualityStocksNewsBreaks – Massimo Group (NASDAQ: MAMO) to Launch Electric UTV in 2026, Expanding Portfolio in Growing Market

Massimo Group (NASDAQ: MAMO), a manufacturer and distributor of powersports vehicles, announced plans to debut its first electric utility terrain vehicle (UTV) in 2026, marking its entry into the fast-growing electric utility vehicle market. Powered by a 72V 200AH lithium battery and a 15KW permanent magnet synchronous motor, the new UTV delivers up to 70 kilometers per charge, real-time 4WD, a top speed of 45 km/h, and a 7-inch (optional 10-inch) touchscreen display. CEO David Shan said the model addresses rising demand among environmentally conscious consumers and agricultural users, while positioning Massimo for significant growth opportunities. To view the full press…

TuesdaySep 16, 2025 10:02 am

QualityStocksNewsBreaks – OptimumBank Holdings, Inc. (NYSE American: OPHC) Engages IBN to Lead Corporate Communications Strategy

OptimumBank Holdings (NYSE American: OPHC), the parent of OptimumBank, a Fort Lauderdale-based community bank with more than $1 billion in assets, has selected IBN to spearhead its corporate communications efforts. OptimumBank, specializing in real estate and commercial lending, ranks among the region’s fastest-growing and most profitable community banks, with return on equity well above industry averages. The bank, which achieved SBA Preferred Lender status in just over two years, continues to scale efficiently while focusing on technology modernization and maintaining its relationship-based banking model. To view the full press release, visit https://ibn.fm/FtnYz About OptimumBank Holdings Inc. OptimumBank was founded in 2000…

TuesdaySep 16, 2025 9:50 am

QualityStocksNewsBreaks – Izotropic Corporation (CSE: IZO) (OTCQB: IZOZF) (FSE: 1R3) Launches FAQ Page to Enhance Transparency and Investor Engagement

Izotropic (CSE: IZO) (OTCQB: IZOZF) (FSE: 1R3), a medical device company advancing imaging-based products for the detection and treatment of breast cancer, has launched a new Frequently Asked Questions page on its corporate website at www.izocorp.com/faq. The resource provides accessible information on the company’s IzoView Breast CT Imaging System, development milestones, and competitive positioning, addressing topics such as breast density, imaging workflow, and comparisons with other modalities. Optimized for search and AI platforms, the FAQ page supports Izotropic’s investor relations, clinical outreach, and advocacy initiatives. To view the full press release, visit https://ibn.fm/I1kkE About Izotropic More information about Izotropic Corporation…

TuesdaySep 16, 2025 9:45 am

Clene Inc.’s (NASDAQ: CLNN) Lead Candidate CNM-Au8(R) Shows Promise in Improving Cellular Health in Parkinson’s Disease

Clene Inc. reported new preclinical data on its drug candidate CNM-Au8 for Parkinson’s disease. The therapy improved mitochondrial health, restored cellular metabolism, reduced inflammation, and normalized gene expression in dopaminergic neurons. Findings were presented at the Michael J. Fox Foundation’s H2 Therapeutics Stewardship Meeting in New York City. CNM-Au8 previously showed positive energetic and metabolic effects in a Phase 2 Parkinson’s trial, aligning with the new preclinical results. The treatment demonstrated no toxicity in neuronal models, consistent with safety data from over 1,000 patient-years in ALS and MS trials. Clene plans to design a Phase 2 clinical study for Parkinson’s…

Site Search

Company Search

Month: September 2025